A detailed history of Synovus Financial Corp transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Synovus Financial Corp holds 11,270 shares of VRTX stock, worth $5.34 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
11,270
Previous 11,153 1.05%
Holding current value
$5.34 Million
Previous $4.66 Million 13.3%
% of portfolio
0.07%
Previous 0.06%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$392.81 - $485.53 $45,958 - $56,807
117 Added 1.05%
11,270 $5.28 Million
Q1 2024

May 14, 2024

BUY
$407.69 - $446.08 $179,383 - $196,275
440 Added 4.11%
11,153 $4.66 Million
Q3 2023

Nov 13, 2023

SELL
$338.18 - $362.46 $498,477 - $534,266
-1,474 Reduced 12.09%
10,713 $3.73 Million
Q2 2023

Aug 08, 2023

BUY
$314.42 - $351.91 $990,423 - $1.11 Million
3,150 Added 34.86%
12,187 $4.29 Million
Q1 2023

May 11, 2023

SELL
$283.23 - $323.1 $258,022 - $294,344
-911 Reduced 9.16%
9,037 $2.85 Million
Q4 2022

Feb 06, 2023

BUY
$285.76 - $321.48 $132,306 - $148,845
463 Added 4.88%
9,948 $2.87 Million
Q3 2022

Oct 27, 2022

BUY
$273.83 - $305.53 $44,634 - $49,801
163 Added 1.75%
9,485 $2.74 Million
Q2 2022

Aug 10, 2022

BUY
$234.96 - $292.55 $607,371 - $756,241
2,585 Added 38.37%
9,322 $2.63 Million
Q1 2022

May 12, 2022

BUY
$221.42 - $260.97 $130,637 - $153,972
590 Added 9.6%
6,737 $1.76 Million
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $984,352 - $1.24 Million
5,561 Added 948.98%
6,147 $1.35 Million
Q3 2021

Nov 08, 2021

SELL
$181.39 - $202.99 $725 - $811
-4 Reduced 0.68%
586 $108,000
Q2 2021

Aug 11, 2021

SELL
$187.49 - $221.1 $1.04 Million - $1.23 Million
-5,564 Reduced 90.41%
590 $118,000
Q1 2021

May 11, 2021

SELL
$207.02 - $241.31 $71,007 - $82,769
-343 Reduced 5.28%
6,154 $1.32 Million
Q4 2020

Feb 11, 2021

BUY
$207.01 - $276.09 $30,223 - $40,309
146 Added 2.3%
6,497 $1.54 Million
Q3 2020

Nov 09, 2020

BUY
$255.65 - $303.1 $1.51 Million - $1.79 Million
5,904 Added 1320.81%
6,351 $1.73 Million
Q2 2020

Aug 10, 2020

SELL
$225.48 - $295.8 $888,165 - $1.17 Million
-3,939 Reduced 89.81%
447 $130,000
Q1 2020

Apr 24, 2020

BUY
$199.77 - $247.81 $786,894 - $976,123
3,939 Added 881.21%
4,386 $1.04 Million
Q4 2019

Feb 06, 2020

BUY
$166.71 - $223.91 $22,172 - $29,780
133 Added 2.08%
6,540 $1.43 Million
Q3 2019

Nov 01, 2019

BUY
$166.23 - $187.09 $10,971 - $12,347
66 Added 17.32%
447 $75,000
Q2 2019

Aug 08, 2019

SELL
$164.61 - $190.37 $1.02 Million - $1.18 Million
-6,183 Reduced 50.24%
6,124 $1.12 Million
Q1 2019

May 09, 2019

SELL
$163.73 - $194.7 $10,314 - $12,266
-63 Reduced 14.19%
381 $70,000
Q4 2018

Feb 07, 2019

SELL
$151.91 - $192.21 $283,312 - $358,471
-1,865 Reduced 80.77%
444 $73,000
Q3 2018

Nov 01, 2018

BUY
$167.73 - $192.74 $15,766 - $18,117
94 Added 4.24%
2,309 $446,000
Q2 2018

Aug 01, 2018

SELL
$145.72 - $169.96 $9,034 - $10,537
-62 Reduced 2.72%
2,215 $378,000
Q1 2018

May 07, 2018

BUY
$151.6 - $177.13 $345,193 - $403,325
2,277 New
2,277 $369,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Synovus Financial Corp Portfolio

Follow Synovus Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Synovus Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Synovus Financial Corp with notifications on news.